593 related articles for article (PubMed ID: 26159700)
1. Developments in the management of idiopathic pulmonary fibrosis.
Drug Ther Bull; 2015 Jul; 53(7):78-81. PubMed ID: 26159700
[TBL] [Abstract][Full Text] [Related]
2. Absence of early metabolic response assessed by 18F-FDG PET/CT after initiation of antifibrotic drugs in IPF patients.
Bondue B; Castiaux A; Van Simaeys G; Mathey C; Sherer F; Egrise D; Lacroix S; Huaux F; Doumont G; Goldman S
Respir Res; 2019 Jan; 20(1):10. PubMed ID: 30646908
[TBL] [Abstract][Full Text] [Related]
3. Pirfenidone for the treatment of idiopathic pulmonary fibrosis.
George PM; Wells AU
Expert Rev Clin Pharmacol; 2017 May; 10(5):483-491. PubMed ID: 28266906
[TBL] [Abstract][Full Text] [Related]
4. Idiopathic pulmonary fibrosis in the era of antifibrotic therapy: Searching for new opportunities grounded in evidence.
Robalo-Cordeiro C; Campos P; Carvalho L; Borba A; Clemente S; Freitas S; Furtado S; Jesus JM; Leal C; Marques A; Melo N; Souto-Moura C; Neves S; Sousa V; Santos A; Morais A
Rev Port Pneumol (2006); 2017; 23(5):287-293. PubMed ID: 28668400
[TBL] [Abstract][Full Text] [Related]
5. [Novel therapies for idiopathic pulmonary fibrosis].
Wand O; Kremer MR
Harefuah; 2015 Jul; 154(7):446-50, 469, 468. PubMed ID: 26380465
[TBL] [Abstract][Full Text] [Related]
6. Advances in Targeted Therapy for Progressive Fibrosing Interstitial Lung Disease.
Gibson CD; Kugler MC; Deshwal H; Munger JS; Condos R
Lung; 2020 Aug; 198(4):597-608. PubMed ID: 32591895
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic targets in idiopathic pulmonary fibrosis.
Kolb M; Bonella F; Wollin L
Respir Med; 2017 Oct; 131():49-57. PubMed ID: 28947042
[TBL] [Abstract][Full Text] [Related]
8. Pirfenidone and Nintedanib in idiopathic pulmonary fibrosis: Real-life experience in an Italian referral centre.
Bargagli E; Piccioli C; Rosi E; Torricelli E; Turi L; Piccioli E; Pistolesi M; Ferrari K; Voltolini L
Pulmonology; 2019; 25(3):149-153. PubMed ID: 30236523
[TBL] [Abstract][Full Text] [Related]
9. Treatment of idiopathic pulmonary fibrosis in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand and the Lung Foundation Australia.
Jo HE; Troy LK; Keir G; Chambers DC; Holland A; Goh N; Wilsher M; de Boer S; Moodley Y; Grainge C; Whitford H; Chapman S; Reynolds PN; Glaspole I; Beatson D; Jones L; Hopkins P; Corte TJ
Respirology; 2017 Oct; 22(7):1436-1458. PubMed ID: 28845557
[TBL] [Abstract][Full Text] [Related]
10. Pirfenidone and Nintedanib for Treatment of Idiopathic Pulmonary Fibrosis.
Sathiyamoorthy G; Sehgal S; Ashton RW
South Med J; 2017 Jun; 110(6):393-398. PubMed ID: 28575896
[TBL] [Abstract][Full Text] [Related]
11. Overview of idiopathic pulmonary fibrosis, evidence-based guidelines, and recent developments in the treatment landscape.
Glassberg MK
Am J Manag Care; 2019 Jul; 25(11 Suppl):S195-S203. PubMed ID: 31419091
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis.
Finnerty JP; Ponnuswamy A; Dutta P; Abdelaziz A; Kamil H
BMC Pulm Med; 2021 Dec; 21(1):411. PubMed ID: 34895203
[TBL] [Abstract][Full Text] [Related]
13. Treatment of idiopathic pulmonary fibrosis with Nintedanib: an update.
Wongkarnjana A; Yanagihara T; Kolb MR
Expert Rev Respir Med; 2019 Dec; 13(12):1139-1146. PubMed ID: 31564185
[No Abstract] [Full Text] [Related]
14. Therapeutic Approach to Adult Fibrotic Lung Diseases.
Adegunsoye A; Strek ME
Chest; 2016 Dec; 150(6):1371-1386. PubMed ID: 27521738
[TBL] [Abstract][Full Text] [Related]
15. Forced vital capacity in idiopathic pulmonary fibrosis--FDA review of pirfenidone and nintedanib.
Karimi-Shah BA; Chowdhury BA
N Engl J Med; 2015 Mar; 372(13):1189-91. PubMed ID: 25806913
[No Abstract] [Full Text] [Related]
16. Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis.
Collins BF; Raghu G
Eur Respir Rev; 2019 Sep; 28(153):. PubMed ID: 31578210
[TBL] [Abstract][Full Text] [Related]
17. Update in diffuse parenchymal lung disease, 2013.
Rosas IO; Kaminski N
Am J Respir Crit Care Med; 2015 Feb; 191(3):270-4. PubMed ID: 25635490
[TBL] [Abstract][Full Text] [Related]
18. Differential Discontinuation Profiles between Pirfenidone and Nintedanib in Patients with Idiopathic Pulmonary Fibrosis.
Takehara K; Koga Y; Hachisu Y; Utsugi M; Sawada Y; Saito Y; Yoshimi S; Yatomi M; Shin Y; Wakamatsu I; Umetsu K; Kouno S; Nakagawa J; Sunaga N; Maeno T; Hisada T
Cells; 2022 Jan; 11(1):. PubMed ID: 35011705
[TBL] [Abstract][Full Text] [Related]
19. Successful Concomitant Therapy with Pirfenidone and Nintedanib in Idiopathic Pulmonary Fibrosis: A Case Report.
Hagmeyer L; Treml M; Priegnitz C; Randerath WJ
Respiration; 2016; 91(4):327-32. PubMed ID: 27073887
[TBL] [Abstract][Full Text] [Related]
20. Nintedanib in the management of idiopathic pulmonary fibrosis: clinical trial evidence and real-world experience.
Rivera-Ortega P; Hayton C; Blaikley J; Leonard C; Chaudhuri N
Ther Adv Respir Dis; 2018; 12():1753466618800618. PubMed ID: 30249169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
